J.M. Ferrero-Cafiero

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Mafalda Oliveira, Claudette Falato, Juan Miguel Cejalvo et al. · Annals of Oncology · 2023 · 37 citations · Full text

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

Tomás Pascual, Mafalda Oliveira, Eva Ciruelos et al. · Frontiers in Oncology · 2021 · 29 citations · Full text

First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat

Rosa María Antonijoan, J.M. Ferrero-Cafiero, Jimena Coimbra et al. · CNS Drugs · 2021 · 18 citations · Full text

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

Fara Brasó‐Maristany, J.M. Ferrero-Cafiero, Claudette Falato et al. · Nature Communications · 2024 · 18 citations · Full text

[P4–576]: FIRST‐IN‐HUMAN PHASE I RESULTS SHOW SAFETY, TOLERABILITY AND BRAIN PENETRANCE OF ORY‐2001, AN EPIGENETIC DRUG TARGETING LSD1 AND MAO‐B

Tamara Maes, César Molinero, Rosa Antonijoan et al. · Alzheimer s & Dementia · 2017 · 13 citations

Epigenetic Change, Psychopharmacology, Pharmacotherapy +18